News
On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...
Hims & Hers will begin offering generic semaglutide drugs in Canada next year after Novo Nordisk lost its exclusive patent ...
Mr Richard Delali Ahedor, the National President of the Ghana Health Information Management Association (GHIMA), has raised ...
This growth is fueled by a surge in startup funding and the introduction of new solutions and services, especially those designed for virtual consultations. Furthermore, integrating artificial ...
1d
Asianet Newsable on MSNHims & Hers Announces Plans To Expand Into Canada As Novo Nordisk’s Weight Loss Drug Patent ExpiresHims & Hers Health, Inc. (HIMS) announced on Wednesday that it will expand to Canada next year with its weight loss program, ...
Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...
StockStory.org on MSN2d
Hims & Hers Health (HIMS) Stock Is Up, What You Need To KnowWhat Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the ...
Exclusive: Capt. Mike Tallon was sent for inpatient treatment, attended AA meetings, and blew into a breathalyzer twice daily ...
Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.
The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results